Decisionability

Decisionability is a specialized clinical trial design and statistical consulting firm that operates as a key brand of Berry Consultants. The company is a global leader in the development and implementation of innovative clinical trial methodologies, including Bayesian adaptive designs and complex platform trials. By leveraging their proprietary Fixed and Adaptive Clinical Trial Simulator (FACTS) software, Decisionability provides pharmaceutical and biotech sponsors with the tools to simulate and optimize trial outcomes before enrollment begins. Their expertise helps drug developers reduce risks, minimize costs, and accelerate the delivery of life-saving therapies to patients. Decisionability has been a primary architect for several landmark trials, such as the I-SPY oncology series and the REMAP-CAP trial for infectious diseases. The firm's work is widely recognized by regulatory agencies, including the FDA and EMA, as a gold standard for modern clinical research design.